Navigation Links
Study Demonstrating Aeolus Compound's Neuroprotection in,Parkinson's Disease Published in the Journal of Neuroscience

LAGUNA NIGUEL, Calif.--(BUSINESS WIRE)--Apr 26, 2007 - Aeolus Pharmaceuticals, Inc. (OTCBB:AOLS) announced today the publication* in the April 18, 2007 issue of the Journal of Neuroscience a study by researchers at the University of Colorado and National Jewish Medical and Research Center demonstrating that the Company's first orally available catalytic antioxidant, AEOL 11207, demonstrated neuroprotection in an animal model of Parkinson's disease ("PD"). The study also showed that the compound has favorable blood-brain barrier permeability.

AEOL 11207 was tested for neuroprotection and oral bio-availability in the mouse MPTP model of Parkinson's disease. AEOL 11207 administered orally protected against MPTP-induced dopamine depletion in the striatum as well as dopaminergic neuronal loss, glutathione depletion, lipid peroxidation, and 3-nitrotyrosine formation in the ventral midbrain. Neuroprotection correlated with brain metalloporphyrin concentrations. The researchers concluded that AEOL 11207 demonstrated neuroprotection in the MPTP mouse model and that the data support further investigation of AEOL 11207 as a potential treatment for PD and other neuro-degenerative diseases.

The Potential for AEOL 11207 in Parkinson's and other Neurodegenerative Diseases

A major hurdle to the treatment of chronic neurodegenerative diseases is the development of efficacious and bioavailable therapeutic agents that permeate the blood-brain barrier. Catalytic removal of reactive species is a highly warranted, yet novel approach for the treatment of age related neurodegenerative diseases such as PD. The major therapeutic approach currently used to alleviate the symptoms of PD involves restoration of dopaminergic neurotransmission using levodopa, dopamine agonists, and inhibitors of monoamine metabolism. However, these therapeutic approaches are often associated with serious adverse effects and fail to provide long-
'"/>




Page: 1 2 3

Related medicine technology :

1. Data Available From Erbitux Phase III Study in First-Line Treatment of Advanced Lung Cancer
2. Clinical Study Shows Regenecare Relieves Pain and Itching of Skin Rashes Caused by Widely Used Cancer Drugs
3. Cell Therapeutics, Inc. Management to Discuss Todays Announcement of Interim Pixantrone Study Results
4. Biofrontera AG Announces Clinical Study Confirms Excellent Efficacy of BF-200 ALA In Actinic Keratosis
5. Reaction to Avandia Warnings Stronger Among Internists Than Endocrinologists, According to Study by GfK Market Measures
6. Portola Pharmaceuticals Announces Positive Data from a Phase II Study of its Factor Xa Inhibitor at the XXI Congress of the International Society on Thrombosis and Haemostasis
7. Actemra (tocilizumab) Third Phase III Study Results Show Significant Improvement in Symptoms of Patients with Rheumatoid Arthritis
8. Protox Announces Positive Clinical Data from Prostate Cancer Study
9. International ENDORSE Study Shows That the Majority of Hospitalized Patients Surveyed are at Risk for VTE and Many do not Receive Recommended VTE prophylaxis
10. New Study Shows That Extending Prophylaxis With Clexane / Lovenox (enoxaparin Sodium Injection) to 5 Weeks is More Effective Than 10 Days for Reducing the Risk of Venous Thromboembolism (VTE) in Acutely ill Medical Patients With Reduced Mobility
11. Genzyme Announces Data from First Phase 3 Study of Tolevamer in Patients with C. difficile Associated Diarrhea
Post Your Comments:
(Date:7/2/2015)... BGI gab heute bekannt, dass ... American College of Pathologists (CAP) akkreditiert wurde. ... klinische Next-Generation-Sequencing Labor, das in ... somit die höchsten Standards an klinischer Laborpraxis ... - 21 CFR Part 11 konformen Laborverfahren ...
(Date:7/2/2015)... , July 2, 2015  AbbVie (NYSE: ... on Friday, July 24, 2015, before the market opens. ... the earnings conference call at 8 a.m. Central time ... Investor Relations website at www.abbvieinvestor.com . An archived ... a.m. Central time. About AbbVie ...
(Date:7/2/2015)... June 25, 2015 Research ... the "Veterinary / Animal Vaccines Market by Product, ... report to their offering. The global animal ... 2020 from $5,507.3 Million in 2015, at a CAGR ... factors fueling market growth are growing prevalence of animal ...
Breaking Medicine Technology:BGI erhält Akkreditierung vom College of American Pathologists (CAP) 2Veterinary / Animal Vaccines Market 2015 - Global Forecast to 2020 for the $7.19 Billion Industry 2
... 2011 BD Biosciences, a segment of BD (Becton, ... new BD Falcon™ Multi-Flask, a multi-layer cell culture device ... easily and more efficiently. Currently, most ... new BD Falcon Multi-Flask, available in both three- and ...
... Thousands of jobs in Texas supported by the biopharmaceutical ... such as imposing new taxes in the Medicare prescription ... From research to technical work, manufacturing to construction ... services, the biopharmaceutical sector supports a broad array of ...
Cached Medicine Technology:BD Biosciences Introduces New Device Designed to Increase Cell Growth and Cell Culture Productivity 2Research Demonstrates Possible Texas Job Losses from Sectors Supported by Biopharmaceutical Companies 2Research Demonstrates Possible Texas Job Losses from Sectors Supported by Biopharmaceutical Companies 3
(Date:7/3/2015)... ... July 03, 2015 , ... ... and speaker lineup for its 2015 Annual Conference , the premiere ... 2015 at the Renaissance Orlando at SeaWorld in Orlando, Florida. Speakers include ...
(Date:7/3/2015)... (PRWEB) , ... July 03, 2015 , ... ... exclusively to healthcare providers, has been retained to lead a national chief ... of the top-ranked executive search firms in the healthcare industry, B. E. Smith ...
(Date:7/3/2015)... ... 2015 , ... Jennifer Renee Hanes, DO is the new Medical Director of ... of independent freestanding emergency rooms in the United States. , “We are excited to ... said Executive Medical Director of First Choice Emergency Room, Dr. James M. Muzzarelli. ...
(Date:7/3/2015)... ... 03, 2015 , ... Every year, One-to-1 Fitness and the Red Deer ... the Red Deer community with free fitness training and indoor fitness boot camp classes ... and entertainment raised thousands of charity dollars and ended with a $10,000 donation to ...
(Date:7/2/2015)... ... 2015 , ... sweetFrog Enterprises, LLC. is pleased to announce the opening of ... located in the Lone Star State. The premium frozen yogurt chain was listed as ... store, which opened July 1 at Duke’s Travel Plaza, is located at:, 30176 Hwy ...
Breaking Medicine News(10 mins):Health News:RNS Announces Sessions and Speaker Lineup for the 2015 Annual Conference of the Rheumatology Nurses Society 2Health News:RNS Announces Sessions and Speaker Lineup for the 2015 Annual Conference of the Rheumatology Nurses Society 3Health News:Jane Phillips Medical Center Retains B. E. Smith to Recruit New Chief Nursing Officer 2Health News:Jane Phillips Medical Center Retains B. E. Smith to Recruit New Chief Nursing Officer 3Health News:Dr. Jennifer Renee Hanes Named by First Choice Emergency Room as Medical Director of Missouri City, TX Facility 2Health News:Dr. Jennifer Renee Hanes Named by First Choice Emergency Room as Medical Director of Missouri City, TX Facility 3Health News:Red Deer Fitness Studio Raises $10,000 for Charity Organization with 24-Hour Train-a-Thon 2Health News:Red Deer Fitness Studio Raises $10,000 for Charity Organization with 24-Hour Train-a-Thon 3Health News:sweetFrog Expands Texas Footprint with Location in Canton 2
... possible to stop tumor growth without harmful therapies, study ... research is moving scientists closer to their goal of ... tissue. , The researchers, who were scheduled to ... Clinical Congress, Oct. 11-15 in Chicago, have created a ...
... Without Relief , WASHINGTON, Oct. 14 Despite ... to raise taxes on the middle class, the House of ... process -- adopting provisions approved yesterday by the Senate Finance ... accounts (FSAs) in order to help pay for health care ...
... PARK, Calif., Oct. 14 New Enterprise Associates, Inc. (NEA), ... Viswanathan, PhD, has been promoted to General Partner. Dr. Viswanathan, ... and growth equity information technology investments, as well as the ... MD, to Principal. Dr. Torti joined NEA in 2007 and ...
... Networks , the nation,s leading provider of physician office-based ... consumer purchase behavior, not just purchase intent, for OTC ... revenue and justify investments designed to capture market share, ... health messages to purchase volume. To address this need ...
... study of over 3,000 adults aged 70-79, the apparent ... functional decline over time did not hold up after ... particular physical activity, body weight, education, and income. ... the Journal of the American Geriatrics Society , ...
... 14 Cardium Therapeutics (NYSE Amex: CXM ) ... clinical trial of Excellarate(TM) for the potential treatment of ... the Company,s Gene Activated Matrix (GAM) technology platform. ... candidate (GAM501, which is a combination of Ad5PDGF-B and ...
Cached Medicine News:Health News:Stem Cells Being Tested to Fight Pancreatic Cancer 2Health News:Fight to Preserve Flexible Spending Accounts Moves to the House of Representatives 2Health News:Fight to Preserve Flexible Spending Accounts Moves to the House of Representatives 3Health News:NEA Promotes Ravi Viswanathan to General Partner and Names Frank Torti to Principal Post 2Health News:NEA Promotes Ravi Viswanathan to General Partner and Names Frank Torti to Principal Post 3Health News:Healthy Advice Networks Now Able to Track Consumer Purchase Behavior 2Health News:Healthy Advice Networks Now Able to Track Consumer Purchase Behavior 3Health News:'Beneficial' effects of alcohol? 2Health News:Cardium Reports Positive Data From Matrix Phase 2b Study of Excellarate(TM) Topical Gel for Non-Healing Diabetic Foot Ulcers and Plans for Phase 3 Program 2Health News:Cardium Reports Positive Data From Matrix Phase 2b Study of Excellarate(TM) Topical Gel for Non-Healing Diabetic Foot Ulcers and Plans for Phase 3 Program 3Health News:Cardium Reports Positive Data From Matrix Phase 2b Study of Excellarate(TM) Topical Gel for Non-Healing Diabetic Foot Ulcers and Plans for Phase 3 Program 4Health News:Cardium Reports Positive Data From Matrix Phase 2b Study of Excellarate(TM) Topical Gel for Non-Healing Diabetic Foot Ulcers and Plans for Phase 3 Program 5Health News:Cardium Reports Positive Data From Matrix Phase 2b Study of Excellarate(TM) Topical Gel for Non-Healing Diabetic Foot Ulcers and Plans for Phase 3 Program 6Health News:Cardium Reports Positive Data From Matrix Phase 2b Study of Excellarate(TM) Topical Gel for Non-Healing Diabetic Foot Ulcers and Plans for Phase 3 Program 7Health News:Cardium Reports Positive Data From Matrix Phase 2b Study of Excellarate(TM) Topical Gel for Non-Healing Diabetic Foot Ulcers and Plans for Phase 3 Program 8Health News:Cardium Reports Positive Data From Matrix Phase 2b Study of Excellarate(TM) Topical Gel for Non-Healing Diabetic Foot Ulcers and Plans for Phase 3 Program 9Health News:Cardium Reports Positive Data From Matrix Phase 2b Study of Excellarate(TM) Topical Gel for Non-Healing Diabetic Foot Ulcers and Plans for Phase 3 Program 10Health News:Cardium Reports Positive Data From Matrix Phase 2b Study of Excellarate(TM) Topical Gel for Non-Healing Diabetic Foot Ulcers and Plans for Phase 3 Program 11Health News:Cardium Reports Positive Data From Matrix Phase 2b Study of Excellarate(TM) Topical Gel for Non-Healing Diabetic Foot Ulcers and Plans for Phase 3 Program 12Health News:Cardium Reports Positive Data From Matrix Phase 2b Study of Excellarate(TM) Topical Gel for Non-Healing Diabetic Foot Ulcers and Plans for Phase 3 Program 13Health News:Cardium Reports Positive Data From Matrix Phase 2b Study of Excellarate(TM) Topical Gel for Non-Healing Diabetic Foot Ulcers and Plans for Phase 3 Program 14
... Riata i lead family ... versatility when managing patients ... (DFTs)., The new Riata ... physicians even more versatility ...
... Millennium™ microsurgical system delivers on the ... technology. For the latest advancement in ... Bausch & Lomb Surgical offers CONCENTRIX™ ... pump to provide both flow and ...
... Microscope with excellent maneuverability. Konan ... weight maintaining high quality. Easy ... by simply changing the adapter. ... has resulted in a sharp ...
To maintain the conjunctival cul-de-sacs after enucleation or evisceration without hindering lid closure....
Medicine Products: